Non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is a leading cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease continuum from steatosis with or without mild inflammation (non-alcoholic fatty liver), to non-alcoholic steatohepatitis (NASH), whic...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The Lancet (British edition) Ročník 397; číslo 10290; s. 2212 - 2224
Hlavní autoři:	Powell, Elizabeth E, Wong, Vincent Wai-Sun, Rinella, Mary
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Ltd 05.06.2021 Elsevier B.V Elsevier Limited
Témata:	Australia Biopsy Carcinoma, Hepatocellular - pathology Cardiovascular diseases Cirrhosis Developmental stages Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Disease Progression Drug approval Drug development Epidemiology Esophagus Fatty liver Fibrosis Gastrointestinal diseases Health aspects Health services Hepatitis Hepatocellular carcinoma Heterogeneity Humans Hypertension Inflammation Liver Liver cancer Liver cirrhosis Liver Cirrhosis - pathology Liver diseases Liver Neoplasms - pathology Malignancy Medical colleges Medical research Medicine, Experimental Metabolic disorders Metabolic syndrome Mortality Natural history Non-alcoholic Fatty Liver Disease - epidemiology Non-alcoholic Fatty Liver Disease - pathology Non-alcoholic Fatty Liver Disease - physiopathology Obesity Phenotypes Population Research institutes Risk factors Steatosis Transplants & implants Type 2 diabetes Weight reduction Australia United States > US
ISSN:	0140-6736, 1474-547X, 1474-547X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!